These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34822801)

  • 1. Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.
    Loomba R; Ratziu V; Harrison SA;
    Gastroenterology; 2022 Mar; 162(3):680-688. PubMed ID: 34822801
    [No Abstract]   [Full Text] [Related]  

  • 2. Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration.
    Anania FA; Dimick-Santos L; Mehta R; Toerner J; Beitz J
    Hepatology; 2021 May; 73(5):2023-2027. PubMed ID: 33340111
    [No Abstract]   [Full Text] [Related]  

  • 3. Adolescents and Drug Development: Commentary on a Dawning Paradigm Shift.
    Kearns GL; van den Anker JN
    J Clin Pharmacol; 2021 Jun; 61(6):740-743. PubMed ID: 33797778
    [No Abstract]   [Full Text] [Related]  

  • 4. Leveraging Clinical Pharmacology to Optimize Drug Development for Nonalcoholic Steatohepatitis and Cholestatic Liver Diseases: Workshop Report.
    Kim I; Seo S
    Clin Pharmacol Ther; 2021 Feb; 109(2):292-294. PubMed ID: 32740920
    [No Abstract]   [Full Text] [Related]  

  • 5. Minors and a Dawning Paradigm Shift in "Pediatric" Drug Development.
    Rose K; Tanjinatus O; Grant-Kels JM; Ettienne EB; Striano P; Neubauer D
    J Clin Pharmacol; 2021 Jun; 61(6):736-739. PubMed ID: 33368372
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints.
    Do A; Ilagan-Ying YC; Mehal WZ; Lim JK
    Expert Opin Drug Discov; 2021 Feb; 16(2):125-134. PubMed ID: 33086894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing Pharmacologic Treatments for Eosinophilic Esophagitis: Draft Guidance from the United States Food and Drug Administration.
    Lyons E; Donohue K; Lee JJ
    Gastroenterology; 2019 Aug; 157(2):275-277. PubMed ID: 31022402
    [No Abstract]   [Full Text] [Related]  

  • 8. Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.
    Vos MB; Dimick-Santos L; Mehta R; Omokaro SO; Taminiau J; Schabel E; Kleiner DE; Szitanyi P; Socha P; Schwimmer JB; Noviello S; Silberg DG; Torstenson R; Miller V; Lavine JE;
    Gastroenterology; 2019 Dec; 157(6):1448-1456.e1. PubMed ID: 31520612
    [No Abstract]   [Full Text] [Related]  

  • 9. 2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists.
    Sudsakorn S; Bahadduri P; Fretland J; Lu C
    Curr Drug Metab; 2020; 21(6):403-426. PubMed ID: 32562522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical efficacy in therapeutic area guidelines from the U.S. Food and Drug Administration and the European Medicines Agency: a cross-sectional study.
    Langhof H; Chin WWL; Wieschowski S; Federico C; Kimmelman J; Strech D
    Br J Pharmacol; 2018 Nov; 175(22):4229-4238. PubMed ID: 30153701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and opportunities in drug development for nonalcoholic steatohepatitis.
    Ocker M
    Eur J Pharmacol; 2020 Mar; 870():172913. PubMed ID: 31926994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Call for Objective Dose Selection to Increase Success in Pediatric Clinical Trials: A Perspective From NICHD and NIMH Program Staff.
    Giacoia G; Grabb MC; Pawlyk AC; Ren Z; Samedy-Bates L; Taylor-Zapata P
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S9-S12. PubMed ID: 34185908
    [No Abstract]   [Full Text] [Related]  

  • 13. Surrogate Endpoints in Pediatric Studies Submitted to the US FDA.
    Green DJ; Sun H; Burnham J; Liu XI; van den Anker J; Temeck J; Yao L; McCune SK; Burckart GJ
    Clin Pharmacol Ther; 2019 Mar; 105(3):555-557. PubMed ID: 30094815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials.
    Aggarwal P; Noureddin M; Harrison S; Jeannin S; Alkhouri N
    Expert Opin Investig Drugs; 2022 Feb; 31(2):163-172. PubMed ID: 35060815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. US FDA draft Guidance Standard for Clinical Trial Imaging Endpoints: more than just imaging?
    Walovitch RC; Chokron P; Agarwal S
    Biomark Med; 2012 Dec; 6(6):839-47. PubMed ID: 23227850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discussion: The role, position, and function of the FDA-The past, present, and future.
    Fleming TR; Demets DL; McShane LM
    Biostatistics; 2017 Jul; 18(3):417-421. PubMed ID: 28633307
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA insists on more women in drug trials.
    Josefson D
    BMJ; 1997 Oct; 315(7112):833. PubMed ID: 9353497
    [No Abstract]   [Full Text] [Related]  

  • 18. Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program.
    Williams RN; Filozof C; Goldstein BJ; Cusi K
    Clin Pharmacol Ther; 2017 Apr; 101(4):444-446. PubMed ID: 28032901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promising therapies for treatment of nonalcoholic steatohepatitis.
    Noureddin M; Zhang A; Loomba R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discussion: The FDA is Unprepared for Personalized Medicine.
    Tabarrok A
    Biostatistics; 2017 Jul; 18(3):403-404. PubMed ID: 28633317
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.